News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's NICE Rejects GlaxoSmithKline (GSK)'s Revolade For Blood Condition


10/27/2010 7:50:15 AM

LONDON (Dow Jones)--The U.K.'s healthcare costs watchdog Wednesday said GlaxoSmithKline PLC's (GSK.LN) Revolade isn't recommended for use on the state-funded National Health Service to treat patients having a rare blood condition.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES